Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepatier Impact on CV Risk and Bone Health in HCV and HIV/HCV Patients
NCT03221582Phase 4Terminated
- Sponsor
- Dallas VA Medical Center
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of grazoprevir in hepatitis C (HCV) (2 arms), sponsored by Dallas VA Medical Center. Primary endpoint: Impact of EBR/GZR HCV therapy on cardiovascular risk and bone health at 48 weeks. Started Aug 2017; status: terminated.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03221582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221582.